STOCK TITAN
  1. Home
  2. News
  3. NLSPW

NLS Pharmaceutics Ltd - NLSPW STOCK NEWS

Welcome to our dedicated news page for NLS Pharmaceutics (Ticker: NLSPW), a resource for investors and traders seeking the latest updates and insights on NLS Pharmaceutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NLS Pharmaceutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NLS Pharmaceutics's position in the market.

News
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
Rhea-AI Summary
NLS Pharmaceutics announced the closing of a registered direct offering of 7,000,000 common shares at $0.25 per share, raising $1.75 million. The company also issued unregistered warrants for 3,500,000 common shares at the same price. The proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
offering
-
News
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
Rhea-AI Summary
NLS Pharmaceutics announces a registered direct offering of 7,000,000 common shares at $0.25 per share, along with a private placement of unregistered warrants to purchase up to 3,500,000 common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
offering
-
News
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Rhea-AI Summary
NLS Pharmaceutics (NLSP) announces a groundbreaking exclusive worldwide license agreement with Aexon Labs, Inc., acquiring global rights to Dual Orexin Receptor Agonists for neurological disorders. The agreement aims to develop compounds targeting orexin receptors for narcolepsy, hypersomnia, and neurodegenerative diseases. NLS plans to focus on disease-modifying compounds to enhance its neuroscience pipeline in sleep medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.72%
Tags
none
News
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Rhea-AI Summary
NLS Pharmaceutics Ltd. announces CEO's attendance at BIO-EUROPE Springtime Partnering Event in Barcelona, Spain. The event aims to facilitate one-to-one meetings for over 3,700 attendees from 2,000+ companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
-
News
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Rhea-AI Summary
NLS Pharmaceutics Ltd. (NLSP) regains compliance with Nasdaq listing requirements, given an additional 180 days to evidence compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
none
-
News
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
Rhea-AI Summary
NLS Pharmaceutics Ltd. announces submission of plan to regain compliance with Nasdaq listing rule 5550(b)(1) after receiving notification of non-compliance due to minimum stockholders' equity requirement. Nasdaq may grant an extension of up to 180 days for compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
News
Notice of Deficiency with Nasdaq Continued Listing Requirements
Rhea-AI Summary
NLS Pharmaceutics Ltd. (NLSP) received a letter from Nasdaq notifying them of non-compliance with the minimum stockholders' equity requirement. They have 45 days to submit a plan to regain compliance and maintain their listing on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NLS Pharmaceutics CEO Issues Letter to Shareholders
Rhea-AI Summary
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) CEO Issues Letter to Shareholders, reporting on the progress made in 2023, including clinical successes, ongoing business development, leadership appointments, and generating pre-approval, non-dilutive revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
Rhea-AI Summary
NLS Pharmaceutics Ltd. (NLSP) has entered into an exclusive worldwide option agreement with Aexon Labs, Inc. to acquire global development and commercialization rights to Aexon Labs' Dual Orexin Receptor Agonists platform. The agreement includes a potentially leading next-generation, first-in-class, oral, dual orexin receptor agonist (AEX-2) with expected clinical development in 2024. NLS will pay $30,000 for the option exclusivity and $170,000 upon execution of the definitive agreement to exercise the option. The transaction will be structured as an exclusive worldwide license for the development and commercialization by NLS of the Aexon Labs' compounds and their derivatives, with Aexon Labs receiving 15% of all proceeds earned by NLS in any future sub-licensing agreements. Eric Konofal, MD, PhD, who works under a part-time consulting agreement for NLS as its Chief Scientific Officer, is the president and founder of Aexon Labs, and owns 59% of Aexon Labs. Alexander Zwyer, Chief Executive Officer of NLS, owns 35% of Aexon Labs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.24%
Tags
none
News
NLS Pharmaceutics Announces Election of Additional Board Members
Rhea-AI Summary
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) announced the election of Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join its board of directors effective January 1, 2024. The company aims to leverage their expertise in sleep medicine, pharmaceutical innovation, entrepreneurship, and fundraising to develop innovative therapies for patients with rare and complex central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
management
Stock NLSPW logo
NLS Pharmaceutics Ltd

Nasdaq:NLSPW

NLSPW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NLSPW Stock Data

18.78M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Zurich

About NLSPW

mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm